Sinocelltech Ltd.

This study tests whether a new drug called SCTB41, when combined with chemotherapy, works better than the standard immunotherapy tislelizumab plus chemotherapy for people with advanced non-small cell lung cancer that has no targetable genetic mutations. The trial has two parts: a…

This study tests an experimental drug called SCT650C in 60 adults with moderate to severe hidradenitis suppurativa (HS), a painful skin condition causing boils and tunnels. The goal is to see if the drug can reduce abscesses and inflammation by at least 75% after 16 weeks. Partic…

This study is testing a drug called SCT800, a lab-made clotting factor, to prevent bleeding episodes in 36 boys with severe hemophilia A who have never been treated before. Participants receive regular infusions of SCT800, and researchers will monitor how many bleeding events occ…

This phase 3 trial tests whether adding the experimental drug SCTC21C to standard chemotherapy (bortezomib, cyclophosphamide, dexamethasone) works better than chemo alone for people newly diagnosed with AL amyloidosis. The study will enroll 90 participants and measure how well th…

This phase 3 trial is testing whether adding an experimental drug called SCTC21C to a standard three-drug regimen (bortezomib, lenalidomide, and dexamethasone) can help people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The study will en…

This phase 3 trial compares a new experimental drug, SCTB14, to the standard immunotherapy pembrolizumab (Keytruda) as a first treatment for people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels (TPS ≥10%). About 246 participants will receive either …

This study tests an experimental drug called SCT520FF for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 82 adults aged 45 to 80 will receive either SCT520FF or an existing treatment (EYLEA) via eye injections. Researchers will check safety, sid…